[HTML][HTML] Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma …

F Bigi, E Manzato, S Barbato, M Talarico, M Puppi… - Pharmaceuticals, 2024 - mdpi.com
This systematic review examines the available clinical data on CD34+ cell mobilization,
collection, and engraftment in multiple myeloma patients treated with the anti-CD38 …

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

J Pu, T Liu, A Sharma, L Jiang, F Wei, X Ren… - … hematology & oncology, 2024 - Springer
The basic idea of modulating the immune system to better recognize and fight tumor cells
has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based …

Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real …

V Strafella, I Attolico, P Carluccio, F Tarantini… - Annals of …, 2024 - Springer
Annals of Hematology comparing 151 NDTEMM patients receiving D-VTd as induction
therapy from February 2022 to July 2023, to a historical control cohort of 64 patients …

Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery

J Mehl, D Akhoundova, U Bacher, B Jeker… - Cancers, 2024 - mdpi.com
Simple Summary Daratumumab is a CD38-targeting antibody that is being increasingly
integrated into first-line multiple myeloma (MM) induction treatment, leading to an improved …

[HTML][HTML] First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell …

M Martino, M Gori, G Porto, G Policastro, M Pitea… - Cancers, 2024 - mdpi.com
Simple Summary Daratumumab (DARA) plus bortezomib, thalidomide, and dexamethasone
(D-VTd) represent the standard of induction care in Europe for autologous stem cell …

Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations

GC Duarte, L Ladvanszky, G Atkinson… - Bone Marrow …, 2024 - nature.com
Impaired post-thaw CD34 cell (postCD34) viability in autologous haematopoietic stem cell
transplant (ASCT) could indicate delayed engraftment where multiple factors might …

Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the …

N Sgherza, P Musto - Mediterranean Journal of Hematology …, 2024 - pmc.ncbi.nlm.nih.gov
Induction combo therapies, including the humanized anti-CD38 monoclonal antibody
daratumumab, followed by CD34+ hematopoietic stem cells (HSCs) collection and …

Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cells in Multiple Myeloma patients

F Bigi, P Tacchetti, A Giorgi, G Mazzocchetti… - Frontiers in …, 2024 - frontiersin.org
The impact of daratumumab on CD34+ haematopoietic stem cell (HSC) mobilisation has
recently been a matter of concern. To address this issue, we compared CD34+ HSC-related …